Skip to main content
. 2022 Apr 13;14(8):1949. doi: 10.3390/cancers14081949

Table 2.

Disease-free survival (DFS) and overall Survival (OS) in early-stage NSCLC with ALK expression.

Study Year Kind of Study Patients (Total/ALK) Stage DFS OS
Kim et al. 2021 Retrospective 203 (12) I–II negative n.s. 1
Chaft et al. 2018 Retrospective 764 (29) I–III negative n.s.
Shin et al. 2018 Retrospective 309 (23) I negative n.s.

1 n.s.: not significant.